WO2004082720A1 - 血友病治療用薬剤及びそれを用いた血友病治療方法 - Google Patents
血友病治療用薬剤及びそれを用いた血友病治療方法 Download PDFInfo
- Publication number
- WO2004082720A1 WO2004082720A1 PCT/JP2004/003560 JP2004003560W WO2004082720A1 WO 2004082720 A1 WO2004082720 A1 WO 2004082720A1 JP 2004003560 W JP2004003560 W JP 2004003560W WO 2004082720 A1 WO2004082720 A1 WO 2004082720A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- gene
- hemophilia
- treating hemophilia
- drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Definitions
- the present invention relates to a drug for treating hemophilia using hollow nanoparticles and a method for treating hemophilia using the same.
- the present invention relates to a drug containing a cell-introducing substance for the treatment of hemophilia inside particles, capable of specifically introducing the cell-introducing substance into cells, and a method for treating hemophilia using the same.
- Methods for introducing a gene into cells include a method of converting the gene into a macromolecule and incorporating the gene by endocytosis (calcium phosphate method, lipofectamine method), and perforating the cell membrane by stimulation with electric pulses.
- Child Methods for introduction are known, and these methods are commonly used in molecular biological experiments today. Although these methods are simple, they cannot be easily applied to cells and tissues inside a living body because they require direct physical damage to the cells and surgical exposure of the gene transfer site. Also, it is difficult to obtain an introduction rate close to 100%.
- a ribosome method is known as a highly safe substance introduction method. Since this method does not damage cells, it can be applied to cells and tissues inside a living body. However, it is difficult to impart a high degree of cell and tissue specificity to ribosomes, which are simple lipids, and the gene transfer rate in vivo is much lower than required. .
- hemophilia is a hereditary disease mainly caused by bleeding due to a deficiency of blood coagulation factors.
- Blood clotting factor VIII (antihemophilic factor) deficiency is hemophilia A
- blood clotting factor IX (Christmas factor) deficiency is hemophilia B. Both are on the X chromosome. It is caused by a genetic abnormality in factor VIII (IX).
- gene transfer using such a virus DNA has a serious problem that the virus non-specifically infects a wide range of cells and the gene is transferred to cells other than the target cells.
- the viral genome itself can be integrated into the chromosome, causing unforeseen side effects in the future.
- this factor VIII is expressed in the liver, e.g. by portal vein administration or by specific transcription of the factor VIII coding sequence and tissue type. Be done It is necessary to link with the control sequence.
- the present inventors have disclosed in Japanese Patent Application Publication No. 2001-31616 98 that hollow hollow particles in which a biorecognition molecule is introduced into a protein having particle forming ability, It proposes a method for specifically and safely transporting and introducing substances (genes, proteins, compounds, etc.) into cells and tissues.
- the present invention has been proposed in view of such a conventional situation, and it is possible to efficiently introduce a gene of a blood coagulation factor into hepatocytes by a simple method and to reduce side effects.
- An object of the present invention is to provide a drug for treating hemophilia, which has extremely low concern, and a method for treating hemophilia using the same.
- the present inventors have conducted intensive studies and found that human hepatitis B virus surface antigen particles containing genes for blood coagulation factors VIII and IX were injected intravenously into experimental animals transplanted with human liver cancer cells.
- the present inventors have found that a gene is specifically introduced into a liver-derived tissue portion to express a blood coagulation factor, which has an effect of treating hemophilia, thereby completing the present invention.
- the drug for treating hemophilia according to the present invention is a drug in which a hollow nanoparticle composed of a protein having particle forming ability contains a gene for treating hemophilia.
- the agent for treating hemophilia according to the present invention includes a gene for treating hemophilia in a hollow nanoparticle in which a biorecognition molecule is introduced into a protein particle obtained by expressing a protein in a eukaryotic cell. It has been done.
- hepatitis B virus surface antigen protein When expressed in eukaryotic cells, this protein is expressed as a membrane protein on the endoplasmic reticulum membrane, accumulated, and released as particles.
- the hollow nanoparticles obtained in this way recognize hepatocytes and specifically Can express the gene specifically in hepatocytes by including a gene for the treatment of hemophilia, specifically blood coagulation factor VIII or IX. Can be done.
- the drug for treating hemophilia according to the present invention can effectively treat hemophilia by a simple method such as intravenous injection, has a very low risk of side effects, and is clinically applicable as it is.
- the method for treating hemophilia according to the present invention is for treating hemophilia by administering the therapeutic agent for treating hemophilia according to the present invention.
- FIG. 1 is a schematic diagram showing each protein region of the HBsAg gene in an example of the present invention.
- FIG. 2 is a schematic explanatory view illustrating the operation of expressing and purifying HBsAg particles using the recombinant yeast in Examples of the present invention.
- FIG. 3 is a view showing the expression effect of blood coagulation factor VIII by HBsAg particles containing the hFVIII gene in Examples of the present invention.
- FIG. 4 is a view showing the expression effect of blood coagulation factor IX by HBsAg particles containing the hFIX gene in Examples of the present invention.
- BEST MODE FOR CARRYING OUT THE INVENTION The hollow nanoparticles according to the present embodiment are specific to any cell or tissue, for example, a hepatocyte or liver tissue by introducing a biorecognition molecule into a protein capable of forming particles. It makes it possible to deliver genes encoding blood coagulation factors VIII and IX. As such a protein having particle forming ability, subviral particles obtained from various viruses can be applied. Specifically Indicates a hepatitis B virus (HBV) surface antigen protein and the like.
- HBV hepatitis B virus
- examples of protein particles composed of protein having such particle forming ability include those obtained by expressing a protein in eukaryotic cells.
- a protein capable of forming particles when expressed in eukaryotic cells, the protein is expressed and accumulated as a membrane protein on the endoplasmic reticulum membrane, and released as particles.
- yeast, genetically modified yeast, insect cells, animal cells, etc. can be applied as eukaryotic cells.
- the present inventors express the HBV surface antigen L protein in a genetically modified yeast, thereby obtaining a yeast-derived lipid bilayer from the expressed HBV surface antigen L protein. And found that oval hollow particles with a minor axis of about 20 nm and a major axis of about 150 nm were formed in which many of the proteins were embedded (J. Bio. Chem., Vol. 267, No. 3, 1953-1961, 1992). Since such particles do not contain any HBV genome or HBV protein, they do not function as viruses and are extremely safe for the human body. In addition, since the hepatocyte-specific receptor responsible for the extremely high infectivity of HBV to hepatocytes is displayed on the particle surface, it is also highly effective as a carrier that specifically transports substances to hepatocytes. .
- Such a method of forming protein particles using genetically modified yeast is suitable in that particles are produced with high efficiency from soluble proteins in bacterial cells.
- insect cells and animal cells are eukaryotic cells that are closer to higher animals than yeast, and are capable of reproducing higher-order structures such as sugar chains that yeast cannot reproduce.
- the conventional insect cell system used baculovirus, which involved virus expression, so that cells were killed or lysed during protein expression.
- the protein is continuously expressed or the protein is degraded by a protease released from dead cells.
- purification of the protein was difficult due to the large amount of fetal calf serum contained in the medium.
- a baculovirus-free insect cell system capable of serum-free culture has been developed and marketed by Invitrogen.
- the receptor surface of the particle surface obtained by the various methods as described above to an arbitrary biorecognition molecule, it can be applied to any cells and tissues other than the hepatocytes. It is possible to transport and introduce substances with extremely high specificity.
- the protein having the particle form performance is not limited to the above-mentioned hepatitis B virus surface antigen protein, but may be any protein as long as it can form particles.
- Natural proteins derived from plant cells, viruses, fungi, etc., and various synthetic proteins are considered.
- a modified one having reduced antigenicity may be used as a biorecognition molecule.
- Biorecognition molecules to be introduced into proteins having particle forming ability include, for example, cell function regulatory molecules such as growth factors and cytokins, cell surface antigens, tissue-specific antigens, and cells and tissues such as receptors.
- molecules derived from viruses, microorganisms, antibodies, sugar chains, and lipids are preferably used. These are appropriately selected depending on the target cell or tissue.
- hemophilia is obtained by incorporating the above-mentioned hollow nanoparticles into genes encoding blood coagulation factors VIII and IX to be introduced into any cell or tissue, for example, liver cells or liver tissue.
- a substance carrier for treating and treating diseases is obtained.
- various methods used in ordinary chemical and molecular biological experimental techniques are applied. For example, an election port method, an ultrasonic method, a simple diffusion method, a method using a charged lipid, and the like are preferably exemplified.
- the effects of the drug of the present invention were actually confirmed by animal experiments, as shown in the Examples below.
- the agent of the present invention containing a gene encoding blood coagulation factor VIII (IX) to a nude mouse transplanted with cells derived from human liver cancer, serum VIII (IX)
- the expression level was confirmed by measuring the expression level.
- the drug was administered by intravenous administration.
- Other methods of administration include oral administration, intramuscular administration, intraperitoneal administration, and subcutaneous administration.
- HBsAg indicates Hepatitis B virus surface Antigen.
- HB s Ag is a coat protein of HBV, and as shown in the schematic diagram of FIG. 1, there are three types of HB s Ag: S protein, M protein, and L protein.
- S protein is an important coat protein common to three types of proteins, and M protein has a 55-amino acid pre-S 2-peptide added to the N-terminal side of S protein. Things.
- the L protein is obtained by adding a pre-S1 peptide consisting of 108 or 119 amino acids to the N-terminal side of the M protein.
- the nucleotide sequence of this L protein is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO: 2.
- the pre-S1 region of the HB s Ag L protein has a site that directly binds to hepatocytes.
- HBV is known to play an important role in binding to hepatocytes (Cell, Vol. 46, 429-436, 1986; J. of Virol., Vol. 73, 2052-2057). , 1 999).
- HBsAg When HBsAg is expressed in eukaryotic cells, the protein is expressed and accumulated as a membrane protein on the endoplasmic reticulum membrane.
- the HBsAg L protein undergoes intermolecular aggregation and is released as particles into the rumen in a budding manner while taking up the endoplasmic reticulum membrane.
- FIG. 2 shows a schematic explanatory diagram of the expression and purification operations of HBsAg particles described in the following Examples.
- a recombinant yeast strain Sacharomyces Cerevisiae AH22R- strain harboring the L protein expression plasmid pGLDLIIP39-RcT was cultured in synthetic mediums Higli-Pi and 8S5N-P400.
- the L protein particles were expressed ( Figures 2a, b). From the genetically modified yeast in the stationary growth phase (after about 72 hours), prepare whole cell extract using Yeast Protein Extraction Reagent (manufactured by Pierce Chemical Co.), and prepare sodium dodecyl sulfate-polyacrylamide. The samples were separated by gel electrophoresis (SDS-PAGE), and HBsAg in the samples was identified by silver staining. This revealed that HBsAg was a protein having a molecular weight of about 52 kDa.
- the recombinant yeast (wet weight 26 g) cultured in the synthetic medium 8S5N-P400 was added to a buffer A solution (7.5 M urea, 0.1 M sodium phosphate (pH 7 2), 15 mM EDTA, 2 mM PMS F, 0.1% Tween80), and suspended in 10 Om1.
- the yeast was disrupted using glass peas in a bead-beader (BEAD-BEATER). After crushing, the supernatant was collected by centrifugation (Fig. 2c, d).
- the HBsAg particles obtained in (5) were incubated at 37 for 12 hours, followed by SDS-PAGE, and identification by silver staining. As a result, it was confirmed that protease from yeast was completely removed in a series of purification steps.
- HBsAg particles prepared by the above method as a gene for treating hemophilia. Then, HBsAg particles containing the hFVIII (hFIX) gene as the agent of the present invention were produced.
- the hFVIII gene and the hFIX gene were encapsulated in the HBsAg particles.
- cPPT. Alb. FIX. Wpre Human Gene Therapy, Vol. 13, 243-260, 2002 was used as the expression vector.
- HBsAg particles containing the hFVIII (hFIX) gene were produced. Specifically, 20 ag of the above-mentioned expression vector was introduced into 100 g of L protein particles in HBsAg particles dissolved in 500 1 of 83 (pH 7.2). In addition, at this time, electroporation was performed using a 4 mm cuvette at 50 V and 750 F by a Gene Pulser II electroporation system (manufactured by Bio-Rad).
- HBsAg particles containing the hFVIII (hFIX) gene expression vector were administered to the above tumor-bearing mice through the tail vein, and blood coagulation factor VII I (IX) in plasma was administered. The amount was measured over time by Enzymimnoassay (ELISA).
- the ELISA was performed using Asserachom VIIIC: Ag kit and Asserachom IX: Ag kit (manufactured by Diagnostics Stago), which are specific to factor VIII and factor IX, respectively.
- a tumor-bearing mouse obtained by administering 1 ⁇ 10 7 human colon cancer-derived cells WiDr was used, and blood coagulation factor VIII (IX) The amount was measured.
- FIG. 3 shows changes in the ratio (%) of the measured amount of blood coagulation factor VIII in plasma to the amount of blood coagulation factor VIII in the positive control plasma of the above kit.
- Fig. 4 shows changes in the concentration of blood coagulation factor IX in plasma.
- Figs. 3 and 4 there was no change over time in the negative control, whereas in mice to which human liver-derived tumor cells (Nue) were administered, the blood was passed after about 10 days.
- Expression of coagulation factors VIII and IX has been observed, reaching expression levels (Cur. Gene Therapy, Vol. 1, 301-305, 2001) that improve "severe" human patients to "moderate” did. Thereafter, this level was maintained for at least one month, and decreased after about 40 days. This decrease in expression is thought to be due to necrosis of cancer derived from tumor cells (Nue).
- the HBsAg particles containing the hFVIII (hFIX) gene as a drug in the present embodiment are capable of gene transfer with extremely high specificity and efficiency to human hepatocytes. It has been confirmed that there is actually a therapeutic effect on hemophilia. In addition, this experiment successfully established a protocol for treating hemophilia with the HBsAg particles containing the hFVIII (hFIX) gene in experimental animals.
- pRRLsinPPTCMVFVIIIpre pRLs inPPTAlbFIXpre
- hFIX hFVIII
- the present invention is not limited thereto. , Vol. 1, 301-305, 2001.
- the light chain and heavy chain of blood coagulation factor VIII may be incorporated into separate vectors, and blood coagulation factor VIII lacking the B domain may be incorporated into the vector.
- the same effect can be obtained.
- the drug for the treatment of hemophilia according to the present invention described above can effectively treat hemophilia by a simple method of intravenous injection, has a very low risk of side effects, and is clinically applicable as it is. It can be used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/549,555 US20060240114A1 (en) | 2003-03-17 | 2004-03-17 | Drug for treating hemophilia and method of treating hemophilia using the same |
EP04721332A EP1609482A4 (en) | 2003-03-17 | 2004-03-17 | MEDICAMENT FOR THE TREATMENT OF HEMOPHILIA AND METHOD FOR THE TREATMENT OF HEMOPHILIA USE OF THE MEDICINAL PRODUCT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-071788 | 2003-03-17 | ||
JP2003071788A JP2004277355A (ja) | 2003-03-17 | 2003-03-17 | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004082720A1 true WO2004082720A1 (ja) | 2004-09-30 |
Family
ID=33027705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003560 WO2004082720A1 (ja) | 2003-03-17 | 2004-03-17 | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060240114A1 (ja) |
EP (1) | EP1609482A4 (ja) |
JP (1) | JP2004277355A (ja) |
CN (1) | CN1787840A (ja) |
WO (1) | WO2004082720A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009150284A2 (es) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Conjugados de apo-a para la administración de compuestos biológicamente activos |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102834104A (zh) * | 2010-02-22 | 2012-12-19 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511423A (ja) * | 1993-06-10 | 1996-12-03 | ジェネティック セラピー,インコーポレイテッド | 血友病治療のためのアデノウイルスベクター |
JPH09503657A (ja) * | 1993-09-15 | 1997-04-15 | チロン ビアジーン インコーポレイティド | 組換えアルファウイルスベクター |
WO2001027303A1 (en) * | 1999-10-12 | 2001-04-19 | The University Of North Carolina At Chapel Hill | Adeno-associated virus vectors encoding factor viii and methods of using the same |
WO2001064930A1 (fr) * | 2000-02-28 | 2001-09-07 | Japan Science And Technology Corporation | Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520259A (zh) * | 2001-04-25 | 2004-08-11 | ���ݴ�ѧУ��ίԱ�� | 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法 |
-
2003
- 2003-03-17 JP JP2003071788A patent/JP2004277355A/ja not_active Withdrawn
-
2004
- 2004-03-17 CN CNA2004800074283A patent/CN1787840A/zh active Pending
- 2004-03-17 US US10/549,555 patent/US20060240114A1/en not_active Abandoned
- 2004-03-17 WO PCT/JP2004/003560 patent/WO2004082720A1/ja not_active Application Discontinuation
- 2004-03-17 EP EP04721332A patent/EP1609482A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511423A (ja) * | 1993-06-10 | 1996-12-03 | ジェネティック セラピー,インコーポレイテッド | 血友病治療のためのアデノウイルスベクター |
JPH09503657A (ja) * | 1993-09-15 | 1997-04-15 | チロン ビアジーン インコーポレイティド | 組換えアルファウイルスベクター |
WO2001027303A1 (en) * | 1999-10-12 | 2001-04-19 | The University Of North Carolina At Chapel Hill | Adeno-associated virus vectors encoding factor viii and methods of using the same |
WO2001064930A1 (fr) * | 2000-02-28 | 2001-09-07 | Japan Science And Technology Corporation | Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules |
Non-Patent Citations (3)
Title |
---|
FOLLENZI A. ET AL: "Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors", HUMAN GENE THERAPY, vol. 13, no. 2, 2002, pages 243 - 260, XP002980267 * |
See also references of EP1609482A4 * |
YAMADA T. ET AL: "Nanoparticles for the delivery of genes and drugs to human hepatocytes", NATURE BIOTECHNOLOGY, vol. 21, no. 8, August 2003 (2003-08-01), pages 885 - 890, XP002980266 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009150284A2 (es) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Conjugados de apo-a para la administración de compuestos biológicamente activos |
Also Published As
Publication number | Publication date |
---|---|
CN1787840A (zh) | 2006-06-14 |
EP1609482A1 (en) | 2005-12-28 |
JP2004277355A (ja) | 2004-10-07 |
EP1609482A4 (en) | 2006-08-09 |
US20060240114A1 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4085231B2 (ja) | タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法 | |
JP4212921B2 (ja) | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 | |
KR100674325B1 (ko) | 단백질 중공 나노 입자 및 이를 이용한 약제 | |
KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
WO2004082720A1 (ja) | 血友病治療用薬剤及びそれを用いた血友病治療方法 | |
KR100632073B1 (ko) | 시스테인 잔기를 변형한 단백질로 이루어지는 중공 나노입자 및 이를 이용한 약제 | |
US20060165726A1 (en) | Remedies with the use of hollow protein nanoparticles presenting growth factor or the like | |
US20220062439A1 (en) | Localized administration of rna molecules for therapy | |
WO2003082343A1 (fr) | Medicaments pour troubles hepatiques a base de nanoparticules proteiques creuses | |
JP2007106752A (ja) | B型肝炎ウイルスタンパク質中空ナノ粒子とリポソームを用いた物質運搬体、ならびに細胞への物質導入方法 | |
CN117736912A (zh) | 基因工程化仿病毒的细菌外膜囊泡及其制备方法和应用 | |
WO2005049824A1 (ja) | 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20048074283 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721332 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721332 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240114 Country of ref document: US Ref document number: 10549555 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10549555 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004721332 Country of ref document: EP |